173 related articles for article (PubMed ID: 35346577)
41. [A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis].
Lian J; Han T; Xiang H; Liu F; Lyu H; Gao Y; Wang F
Zhonghua Gan Zang Bing Za Zhi; 2015 Oct; 23(10):733-7. PubMed ID: 26573188
[TBL] [Abstract][Full Text] [Related]
42. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
Yue-Meng W; Li YH; Wu HM; Yang J; Xu Y; Yang LH; Yang JH
Clin Exp Med; 2017 May; 17(2):233-241. PubMed ID: 27094312
[TBL] [Abstract][Full Text] [Related]
43. Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial.
Li X; Zhou D; Chi X; Li Q; Wang L; Lu B; Mao D; Wu Q; Wang X; Zhang M; Xue J; Li Y; Lu W; Guo J; Jiang F; Zhang X; Li Z; Yang X; Guo H; Gan D; He L; Luo L; Zhang L; Du H; Ye Y
Hepatol Int; 2020 Dec; 14(6):985-996. PubMed ID: 33128206
[TBL] [Abstract][Full Text] [Related]
44. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
[TBL] [Abstract][Full Text] [Related]
45. Histological Outcome of Fuzheng Huayu plus Entecavir Combination Therapy in Chronic Hepatitis B Patients with Significant Liver Fibrosis.
Gui HL; Zhao CQ; Wang Y; Gu HT; Wang WJ; Cai W; Guo Q; Bao SS; Xu LM; Xie Q
J Clin Transl Hepatol; 2020 Sep; 8(3):277-284. PubMed ID: 33083250
[No Abstract] [Full Text] [Related]
46. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
Doğan ÜB; Kara B; Gümürdülü Y; Soylu A; Akin MS
Turk J Gastroenterol; 2012 Jun; 23(3):247-52. PubMed ID: 22798114
[TBL] [Abstract][Full Text] [Related]
47. [Efficacy Observation of Yiguanjian Decoction Combined Adefovir Dipivoxil Tablet in Treating HBeAg Negative Chronic Viral Hepatitis B Active Compensated Liver Cirrhosis Patients].
Duan SH; Bao ZY; Yuan XD; Wang L; Liu MS
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 May; 36(5):535-8. PubMed ID: 27386642
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice.
Ridruejo E; Marciano S; Galdame O; Reggiardo MV; Muñoz AE; Adrover R; Cocozzella D; Fernandez N; Estepo C; Mendizabal M; Romero GA; Levi D; Schroder T; Paz S; Fainboim H; Mandó OG; Gadano AC; Silva MO
Ann Hepatol; 2014; 13(3):327-36. PubMed ID: 24756007
[TBL] [Abstract][Full Text] [Related]
49. [Study of xiaozhang recipe combined with lamivudine in treatment of 84 chronic viral hepatitis B patients with compensated liver cirrhosis].
Zhou ZH; Li M; Huang LY
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Sep; 31(9):1220-3. PubMed ID: 22013800
[TBL] [Abstract][Full Text] [Related]
50. Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.
Keating GM
Drugs; 2011 Dec; 71(18):2511-29. PubMed ID: 22141390
[TBL] [Abstract][Full Text] [Related]
51. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
[TBL] [Abstract][Full Text] [Related]
52. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.
Kim HR; Yim HJ; Kang S; Suh SJ; Kim SY; Hyun JJ; Koo JS; Kim JH; Seo YS; Yeon JE; Lee SW; Byun KS; Um SH
Liver Int; 2015 Mar; 35(3):860-9. PubMed ID: 24905912
[TBL] [Abstract][Full Text] [Related]
54. Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China.
Li X; Zhang L; Qiu M; Huang Y; Xiao H; Lu B; Jiang Y; Long F; Lin H; He J; Wu Q; Zhang M; Wang L; Zhu X; Gong M; Sun X; Sun J; Sun F; Lu W; Xu W; Chen G; Li Z; Gan D; Yang X; Du H; Ye Y
Trials; 2020 Aug; 21(1):708. PubMed ID: 32787905
[TBL] [Abstract][Full Text] [Related]
55. The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis.
Peng D; Xing HY; Li C; Wang XF; Hou M; Li B; Chen JH
BMC Gastroenterol; 2020 Oct; 20(1):348. PubMed ID: 33076834
[TBL] [Abstract][Full Text] [Related]
56. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
[TBL] [Abstract][Full Text] [Related]
57. Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue.
Ramji A; Doucette K; Cooper C; Minuk GY; Ma M; Wong A; Wong D; Tam E; Conway B; Truong D; Wong P; Barrett L; Ko HH; Haylock-Jacobs S; Patel N; Kaplan GG; Fung S; Coffin CS
World J Gastroenterol; 2022 Aug; 28(31):4390-4398. PubMed ID: 36159017
[TBL] [Abstract][Full Text] [Related]
58. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.
Okada M; Enomoto M; Kawada N; Nguyen MH
Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1095-1104. PubMed ID: 28752768
[TBL] [Abstract][Full Text] [Related]
59. [Effects of Fuzheng Huayu Capsule on the ratio of TGF-beta1/BMP-7 of chronic viral hepatitis B fibrosis patients of Gan-Shen insufficiency blood-stasis obstruction syndrome].
Tang CL; Zhou Z; Shi WQ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jan; 32(1):20-4. PubMed ID: 22500384
[TBL] [Abstract][Full Text] [Related]
60. [Antiviral and antifibrotic therapies reduce occurrence of hepatocellular carcinoma in patients with chronic hepatitis B and liver fibrosis: a 144-week prospective cohort study].
Zhou Y; Hu C; Yuan G; Liu J; Ren Y; Tang C; Yang S; Dai L; Li Y; Yang D
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):633-640. PubMed ID: 31270040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
